Free Trial
→ 2025: Crypto Opportunities You Can’t Afford to Miss (From Darwin) (Ad)

111 Q1 2023 Earnings Report

111 logo
$0.43 0.00 (-0.70%)
As of 01/17/2025 04:00 PM Eastern
Earnings HistoryForecast

111 EPS Results

Actual EPS
-$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

111 Revenue Results

Actual Revenue
$538.29 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

111 Announcement Details

Quarter
Q1 2023
Date
6/15/2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Full Screen Slide Deck
Powered by Quartr

111 Earnings Headlines

111 (NASDAQ:YI) Receives Sell (E+) Rating from Weiss Ratings
January 20 at 2:09 AM | americanbankingnews.com
111 Stock Set to Reverse Split on Friday, January 24th (NASDAQ:YI)
January 16, 2025 | americanbankingnews.com
This red-hot crypto opportunity could slam shut soon
The situation is clear: Crypto is a HUGE hit with investors. Bitcoin became so outrageously popular that early adopters had a shot at absolutely outrageous 14,510% gains or more over the last decade. And it’s far from the only time traders had a shot at obscene gains on crypto. With Ethereum, lucky traders who put $1,000 in 5 years ago and held through the ups and downs would have seen it turn into a staggering $709,740. And now there is a NEW blockchain seeing rapid adoption…
January 21, 2025 | Wealthpin Pro (Ad)
111, Inc. Announces ADS Ratio Change
January 8, 2025 | prnewswire.com
Jokic and Nuggets beat the Spurs 122-111 in overtime on Saturday
January 7, 2025 | yahoo.com
111, Inc. (NASDAQ:YI) Q3 2024 Earnings Call Transcript
November 29, 2024 | msn.com
See More 111 Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 111? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 111 and other key companies, straight to your email.

About 111

111 (NASDAQ:YI) engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.

View 111 Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles